

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Neurizon Therapeutics Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sergio Duchini
Date of last notice	2 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Kelbury Pty Ltd Mr Duchini is a Director of the above holder which is the registered holder of the securities
Date of change	19 March 2026
No. of securities held prior to change	<u>Indirect</u> 1,732,456 fully paid ordinary shares <u>Direct</u> 960,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032
Class	Fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	<u>Indirect</u> 1,875,000 fully paid ordinary shares
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.08 per Share (\$150,000.00)
No. of securities held after change	<u>Indirect</u> 3,607,456 fully paid ordinary shares <u>Direct</u> 960,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Placement as announced on 23 December 2025 and as approved by shareholders at the Company's General Meeting held on 20 February 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Neurizon Therapeutics Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr. Michael Thurn
Date of last notice	23 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C> Mr Thurn is a beneficiary of the above holder which is the registered holder of the securities Dr Michael Thurn <Thurn Family A/C> Mr Thurn is a beneficiary of the above holder which is the registered holder of the securities
Date of change	19 March 2026

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<u>Indirect – Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C></u> - 2,987,720 fully paid ordinary shares - 500,000 Listed Options (NUZOA), expiring 30 April 2026 @ \$0.15 <u>Direct</u> - 1,140,000 Performance Rights expiring 30/06/2027 - 4,256,000 Unlisted Options, expiring 30/06/2032 @ \$0.20
Class	Fully paid ordinary shares
Number acquired	<u>Indirect</u> 500,000 fully paid ordinary shares
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.08 per Share (\$40,000.00)
No. of securities held after change	<u>Indirect – Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C></u> - 3,487,720 fully paid ordinary shares - 500,000 Listed Options (NUZOA), expiring 30 April 2026 @ \$0.15 <u>Direct</u> - 1,140,000 Performance Rights expiring 30/06/2027 - 4,256,000 Unlisted Options, expiring 30/06/2032 @ \$0.20
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Placement as announced on 23 December 2025 and as approved by shareholders at the Company's General Meeting held on 20 February 2026.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Neurizon Therapeutics Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Marcus Hughes
Date of last notice	3 February 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C> Marcus Hughes is a beneficiary of the above holder which is the registered holder of the securities Ms Antoinette Quinlan Spouse of Marcus Hughes
Date of change	19 March 2026

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<u>Direct</u> - 13,110,746 fully paid ordinary shares - 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032 <u>Indirect - Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C></u> - 2,085,895 fully paid ordinary shares <u>Indirect – Ms Antoinette Quinlan</u> - 423,895 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	<u>Direct</u> 7,000,000 fully paid ordinary shares
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.08 per Share (\$560,000.00)
No. of securities held after change	<u>Direct</u> - 20,110,746 fully paid ordinary shares - 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032 <u>Indirect - Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C></u> - 2,085,895 fully paid ordinary shares <u>Indirect – Ms Antoinette Quinlan</u> - 423,895 fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Placement as announced on 23 December 2025 and as approved by shareholders at the Company's General Meeting held on 20 February 2026.
--	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Neurizon Therapeutics Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Kathryn MacFarlane
Date of last notice	2 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	19 March 2026
No. of securities held prior to change	346,492 fully paid ordinary shares 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032
Class	Fully paid ordinary shares
Number acquired	125,000 fully paid ordinary shares
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.08 per Share (\$10,000.00)
No. of securities held after change	471,492 fully paid ordinary shares 600,000 unlisted options, exercisable at \$0.20 (20 cents) each, expiring 30 June 2032
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Placement as announced on 23 December 2025 and as approved by shareholders at the Company's General Meeting held on 20 February 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.